HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

myristyl nicotinate

structure in first source

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Nicotinic Acids: 13
      - Niacin: 3030
        myristyl nicotinate: 4
- Heterocyclic Acids
  - Nicotinic Acids: 13
    - Niacin: 3030
      - myristyl nicotinate: 4

Experts

1.	Tashtoush, Bassam M: 3 articles (07/2013 - 02/2007)
2.	Jacobson, Elaine L: 3 articles (11/2007 - 12/2005)
3.	Jacobson, Myron K: 3 articles (11/2007 - 12/2005)
4.	Kim, Hyuntae: 2 articles (11/2007 - 12/2005)
5.	Al-Taani, Bashar M: 1 article (07/2013)
6.	Bennamani, Amina N: 1 article (07/2013)
7.	DeWald, Tad P: 1 article (02/2007)
8.	Qasem, Jaber: 1 article (02/2007)
9.	Williams, Joshua D: 1 article (02/2007)
10.	Catz, Paul: 1 article (12/2005)

Related Diseases

1.	Flushing 02/19/2007 - "The formulation stability of myristyl nicotinate is crucial because even small amounts of free nicotinic acid cause skin flushing, an effect that is not harmful but would severely limit tolerability. " 07/01/2013 - "The aim of this investigation was to develop a suitable formulation or select a suitable vehicle for the transdermal delivery of highly lipophilic prodrugs of nicotinic acid (dodecyl and myristyl nicotinate) designed to deliver nicotinic acid through skin without causing vasodilatation and flushing and optimizing its delivery to the blood stream. "
2.	Atopic Dermatitis (Atopic Eczema) 02/19/2007 - "Myristyl nicotinate is an ester prodrug under development for delivery of nicotinic acid to skin for treatment and prevention of conditions that involve skin barrier impairment such as chronic photodamage and atopic dermatitis or for mitigating skin barrier impairment that results from therapy such as retinoids or steroids. " 11/01/2007 - "We have evaluated the compatibility of myristyl nicotinate, an agent that enhances skin barrier function, with drugs used to treat conditions where skin barrier impairment is present including photodamage (retinoic acid), atopic dermatitis (hydrocortisone, triamcinolone acetonide), rosacea (metronidazole), and seborrheic dermatitis (ketoconazole). "
3.	Actinic Keratosis 12/27/2005 - "Myristyl nicotinate (Nia-114) is an ester prodrug being developed for delivery of nicotinic acid (NIC) into the skin for prevention of actinic keratosis and its progression to skin cancer. "
4.	Skin Neoplasms (Skin Cancer) 12/27/2005 - "Myristyl nicotinate (Nia-114) is an ester prodrug being developed for delivery of nicotinic acid (NIC) into the skin for prevention of actinic keratosis and its progression to skin cancer. "
5.	Seborrheic Dermatitis 11/01/2007 - "We have evaluated the compatibility of myristyl nicotinate, an agent that enhances skin barrier function, with drugs used to treat conditions where skin barrier impairment is present including photodamage (retinoic acid), atopic dermatitis (hydrocortisone, triamcinolone acetonide), rosacea (metronidazole), and seborrheic dermatitis (ketoconazole). "

Related Drugs and Biologics

1.	Prodrugs
2.	Niacin (Nicotinic Acid)
3.	Esters
4.	Triamcinolone Acetonide (Azmacort)
5.	Tretinoin (Retinoic Acid)
6.	Steroids
7.	Retinoids
8.	Metronidazole (Metric)
9.	Ketoconazole (Nizoral)
10.	Hydrocortisone (Cortisol)

Related Therapies and Procedures

1.	Therapeutics